|
1
|
Zhu AX: Molecularly targeted therapy for
advanced hepatocellular carcinoma in 2012: Current status and
future perspectives. Semin Oncol. 39:493–502. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Psyrri A, Arkadopoulos N, Vassilakopoulou
M, Smyrniotis V and Dimitriadis G: Pathways and targets in
hepatocellular carcinoma. Expert Rev Anticancer Ther. 12:1347–1357.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Li P, Tao L, Yang J, Cai H, Ju X, Li J,
Shao P, Cao Q, Qin C, Meng X and Yin C: Sprouty2 is associated with
prognosis and suppresses cell proliferation and invasion in renal
cell carcinoma. Urology. 82:253e1–e7. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mei Y, Bian C, Li J, Du Z, Zhou H, Yang Z
and Zhao RC: miR-21 modulates the ERK-MAPK signaling pathway by
regulating SPRY2 expression during human mesenchymal stem cell
differentiation. J Cell Biochem. 114:1374–1384. 2013. View Article : Google Scholar
|
|
5
|
Song K, Gao Q, Zhou J, Qiu SJ, Huang XW,
Wang XY and Fan J: Prognostic significance and clinical relevance
of Sprouty 2 protein expression in human hepatocellular carcinoma.
Hepatobiliary Pancreat Dis Int. 11:177–184. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ambros V: The functions of animal
microRNAs. Nature. 431:350–355. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Coulouarn C, Factor VM, Andersen JB,
Durkin ME and Thorgeirsson SS: Loss of miR-122 expression in liver
cancer correlates with suppression of the hepatic phenotype and
gain of metastatic properties. Oncogene. 28:3526–3536. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Furuta M, Kozaki KI, Tanaka S, Arii S,
Imoto I and Inazawa J: miR-124 and miR-203 are epigenetically
silenced tumor-suppressive microRNAs in hepatocellular carcinoma.
Carcinogenesis. 31:766–776. 2010. View Article : Google Scholar
|
|
11
|
Wang W, Zhao LJ, Tan YX, Ren H and Qi ZT:
MiR-138 induces cell cycle arrest by targeting cyclin D3 in
hepatocellular carcinoma. Carcinogenesis. 33:1113–1120. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yin W, Zhao Y, Ji YJ, Tong LP, Liu Y, He
SX and Wang AQ: Serum/plasma microRNAs as biomarkers for
HBV-related hepatocellular carcinoma in China. Biomed Res Int.
2015:9651852015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhuo L, Liu J, Wang B, Gao M and Huang A:
Differential miRNA expression profiles in hepatocellular carcinoma
cells and drug-resistant sublines. Oncol Rep. 29:555–562. 2013.
|
|
14
|
Valencia-Quintana R, Sánchez-Alarcón J,
Tenorio-Arvide MG, Deng Y, Montiel-González JM, Gómez-Arroyo S,
Villalobos-Pietrini R, Cortés-Eslava J, Flores-Márquez AR and
Arenas-Huertero F: The microRNAs as potential biomarkers for
predicting the onset of aflatoxin exposure in human beings: A
review. Front Microbiol. 5:1022014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
16
|
Lewis BP, Burge CB and Bartel DP:
Conserved seed pairing, often flanked by adenosines, indicates that
thousands of human genes are microRNA targets. Cell. 120:15–20.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Zhang Y, Guo X, Xiong L, Kong X, Xu Y, Liu
C, Zou L, Li Z, Zhao J and Lin N: MicroRNA-101 suppresses
SOX9-dependent tumorigenicity and promotes favorable prognosis of
human hepatocellular carcinoma. FEBS Lett. 586:4362–4370. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Heo MJ, Kim YM, Koo JH, Yang YM, An J, Lee
SK, Lee SJ, Kim KM, Park JW and Kim SG: microRNA-148a dysregulation
discriminates poor prognosis of hepatocellular carcinoma in
association with USP4 overexpression. Oncotarget. 5:2792–2806.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Her GM, Hsu CC, Hong JR, Lai CY, Hsu MC,
Pang HW, Chan SK and Pai WY: Overexpression of gankyrin induces
liver steatosis in zebrafish (Danio rerio). Biochim Biophys Acta.
1811:536–548. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Ishteiwy RA, Ward TM, Dykxhoorn DM and
Burnstein KL: The microRNA −23b/−27b cluster suppresses the
metastatic phenotype of castration-resistant prostate cancer cells.
PLoS One. 7:e521062012. View Article : Google Scholar
|
|
21
|
Wan L, Zhang L, Fan K and Wang J: MiR-27b
targets LIMK1 to inhibit growth and invasion of NSCLC cells. Mol
Cell Biochem. 390:85–91. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lee JJ, Drakaki A, Iliopoulos D and Struhl
K: MiR-27b targets PPARγ to inhibit growth, tumor progression and
the inflammatory response in neuroblastoma cells. Oncogene.
31:3818–3825. 2012. View Article : Google Scholar :
|
|
23
|
Jin L, Wessely O, Marcusson EG, Ivan C,
Calin GA and Alahari SK: Prooncogenic factors miR-23b- and miR-27b
are regulated by Her2/Neu, EGF, and TNF-α in breast cancer. Cancer
Res. 73:2884–2896. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen L, Li H, Han L, Zhang K, Wang G, Wang
Y, Liu Y, Zheng Y, Jiang T, Pu P, et al: Expression and function of
miR-27b in human glioma. Oncol Rep. 26:1617–1621. 2011.PubMed/NCBI
|
|
25
|
Yoshitaka T, Kawai A, Miyaki S, Numoto K,
Kikuta K, Ozaki T, Lotz M and Asahara H: Analysis of microRNAs
expressions in chondrosarcoma. J Orthop Res. 31:1992–1998. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lee SA, Ho C, Roy R, Kosinski C, Patil MA,
Tward AD, Fridlyand J and Chen X: Integration of genomic analysis
and in vivo transfection to identify sprouty 2 as a candidate tumor
suppressor in liver cancer. Hepatology. 47:1200–1210. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang C, Delogu S, Ho C, Lee SA, Gui B,
Jiang L, Ladu S, Cigliano A, Dombrowski F, Evert M, et al:
Inactivation of Spry2 accelerates AKT-driven hepatocarcinogenesis
via activation of MAPK and PKM2 pathways. J Hepatol. 57:577–583.
2012. View Article : Google Scholar : PubMed/NCBI
|
